Mechanism of Action: Androgen Receptor Antagonists

Drugs with Mechanism of Action: Androgen Receptor Antagonists

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astellas	XTANDI	enzalutamide	CAPSULE;ORAL	203415-001	Aug 31, 2012		RX	Yes	Yes
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-002	Aug 4, 2020	AB	RX	Yes	Yes			Y	Y
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-001	Aug 4, 2020	AB	RX	Yes	No			Y
Astellas	XTANDI	enzalutamide	CAPSULE;ORAL	203415-001	Aug 31, 2012		RX	Yes	Yes			Y	Y
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-002	Aug 4, 2020	AB	RX	Yes	Yes
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-001	Aug 4, 2020	AB	RX	Yes	No

Last updated: June 26, 2026

Androgen Receptor Antagonists Market Dynamics and Patent Landscape: What Patents Protect AR Blockers, When Exclusivity Expires, and Where Generic Risk Rises

Androgen receptor (AR) antagonists used in advanced prostate cancer sit at the intersection of FDA exclusivity, entrenched formulation and method-of-use IP, and a steady pipeline of Paragraph IV (PIV) generic challenges. Market dynamics are dominated by (1) how quickly firms can convert patent wins into launch, (2) payer access and sequencing versus AR pathway inhibitors and chemotherapies, and (3) whether second-generation AR antagonists and combination regimens have separate patent “islands” that delay generic entry.

This landscape focuses on commercially meaningful small-molecule AR antagonists in metastatic castration-resistant prostate cancer (mCRPC) and related settings, with emphasis on Orange Book status, typical exclusivity horizons, and the most common patent families that extend AR antagonist economics beyond primary composition coverage: solid-state/formulation, crystalline forms/polymorphs, dosing regimens, and combination-method-of-use patents.

---

Which androgen receptor antagonists have the most patent and market exposure in mCRPC?

Featured snippet answer: In mCRPC, the highest patent and market exposure among AR antagonists is concentrated in enzalutamide, apalutamide, and darolutamide, with strong follow-on IP around formulations and dosing regimens, plus ongoing litigation and generic-entry risk management through settlement and exclusivity stacking.

Enzalutamide (Xtandi): AR antagonist with the largest mature economics

• Indication intensity: metastatic and non-metastatic castration-resistant prostate cancer settings drive broad payer footprint.
• IP reality: by the time generics arrive, the estate typically pivots from composition-of-matter to formulation and method-of-use patents.
• Generic risk profile: PIV filings are often used to create leverage for design-around claims and negotiated “at-risk” timing.

Apalutamide (Erleada): AR antagonist tied to earlier disease stages

• Indication breadth: earlier-stage mHSPC and nmCRPC increase volume and durability.
• IP structure: follow-on patents commonly target crystallinity/polymorph control and dosage-form stability.

Darolutamide (Nubeqa): AR antagonist with distinct chemical and formulation IP

• Lower drug-drug interaction profile has supported steady uptake.
• IP structure: formulation and solid-state patents can delay interchangeability even after primary active ingredient coverage ends.

Other AR antagonists and AR pathway competitors

Other agents with AR-axis engagement (including CYP/AR-signaling modulators and steroidogenesis inhibitors) compete for sequencing dollars. They also influence patent strategy indirectly because payers and physicians choose regimens based on overall survival, tolerability, and monitoring burden, not only AR receptor binding potency.

---

What patents protect enzalutamide, apalutamide, and darolutamide (and how do they extend exclusivity)?

Featured snippet answer: AR antagonists typically have layered protection: composition-of-matter, then crystalline forms, polymorphs, particle size and solvate control, solid dosage formulations, and method-of-use or treatment-regimen claims for specific patient subsets and lines of therapy.

Typical patent family structure for AR antagonists

1. Composition-of-matter (primary)
   • Active ingredient and core chemical scaffold.
2. Salt/crystal/polymorph/solvate families
   • Different solid-state forms with improved stability, manufacturability, or bioavailability.
3. Formulation and dosage-form patents
   • Tablet composition, coatings, excipients, disintegration and dissolution characteristics.
4. Process/manufacturing method patents
   • Specific steps, intermediates, or purification conditions.
5. Method-of-use patents
   • Treatment regimens, sequencing, and patient population definitions (for example: post-docetaxel, chemotherapy-naïve, nmCRPC, mHSPC).
6. Combination regimen patents
   • AR antagonist plus agent-specific pairings in defined lines or subgroups.

Patent estate map (high-level, market-relevant)

Below is a business-useful way to think about “what extends the cash register” even after primary active ingredient patents expire.

Patent layer	What it protects	Why it matters for generic entry
Polymorph/crystal/solvate	Solid-state form	Generics may need a new form or show equivalence non-infringement
Formulation	Tablet/capsule composition and release	Even if active ingredient is “off,” dosage form can be blocked
Method-of-use	Defined therapy regimens	PIV challenges can be delayed by surviving use claims
Combination regimens	Specific co-therapy instructions	Affects whether generic can launch for all indications
Manufacturing method	Synthesis and purification steps	Can create process-based infringement hooks for contract manufacturers

Claim targets that repeatedly show up in ANDA litigation

• “Crystalline” and “substantially pure” ranges
• Solvate presence and water content thresholds
• Tablet excipient ratios and dissolution profiles
• Patient selection language tied to PSA kinetics and disease state

---

When does exclusivity end for androgen receptor antagonists, and what timing triggers PIV?

Featured snippet answer: Exclusivity is not a single clock. For small molecules, generic timing is driven by (a) patent expirations listed in the Orange Book, (b) periods of statutory exclusivity where applicable, and (c) whether a generic can file PIV at a point when the FDA can accept an ANDA and the legal case is ripe.

How exclusivity timelines usually stack in AR antagonist cases

• Regulatory exclusivity vs. patent term
  • Orange Book patents end the ability to commercialize without resolution, even if some regulatory exclusivity has lapsed.
• New use approvals
  • Additional indications can add new Orange Book listings and shift the “last patent standing” even for the same active ingredient.
• Combination label expansions
  • New labeled combinations create additional method-of-use and combination patents that often become PIV targets.

Launch risk windows (practical lens)

Event	What it changes	Generic relevance
Primary composition expiration	Removes baseline chemical barrier	Often followed by formulation and use claims
Crystalline/formulation patent expiry	Enables some manufacturing routes	If still blocked by method-of-use patents, launch can stay limited
Last-use patent expiry	Removes remaining “how to treat” restrictions	Many disputes focus here
Settlement “design-around” terms	Defines launch date and scope	Determines at-risk vs. guaranteed launch

---

Which Paragraph IV challenges have targeted AR antagonists, and what do settlement patterns show?

Featured snippet answer: PIV litigation for AR antagonists tends to be concentrated around the last surviving formulation and method-of-use patents; settlements often fix a defined launch date and include market-allocation or covenant structures that reduce uncertainty.

What to look for in PIV litigation involving AR antagonists

1. Which Orange Book patents the ANDA addresses
   • If PIV claims only composition patents, later formulation/use patents can still block.
2. Court decisions on claim construction
   • Crystalline form and “substantially” thresholds often decide infringement reach.
3. Settlement scope
   • Whether the settlement covers all indications or only certain labeled strengths/dosage forms.

Typical settlement mechanics in this space

• Licensing or covenant-not-to-sue in exchange for fixed payment or royalties (varies case-by-case).
• Carve-outs for additional patents not litigated.
• Provisions that constrain launch timing but allow manufacturing earlier than marketing.

Business implication

• Generic entrants often win “time-to-market” not by invalidating the entire estate, but by obtaining consent to launch against a subset of patents on a defined schedule.

---

What is the Orange Book status of androgen receptor antagonists?

Featured snippet answer: Orange Book coverage for AR antagonists generally includes multiple patents across composition, formulation, and method-of-use categories. The practical “Orange Book status” is the count of unexpired patents at the time of the generic filing and whether those patents include method-of-use claims.

Orange Book check logic for AR antagonist entries

• Identify:
  • active ingredient entry,
  • dosage forms and strengths,
  • all unexpired Orange Book patents by expiration date,
  • whether any unexpired patents map to the strength/dosage-form the generic intends to market.
• Then determine:
  • which patents are asserted in the PIV action,
  • whether the litigation includes method-of-use claims (common),
  • whether a settlement modifies the expected launch.

Why “counting patents” alone is misleading

• Some patents are easy to design around, others define the solid-state form or dosing. Courts often focus on claim scope and whether the ANDA’s formulation is “close enough” to infringe.

---

How does darolutamide compare with enzalutamide and apalutamide on patent durability and generic-entry barriers?

Featured snippet answer: Darolutamide’s distinct chemical identity and separate formulation IP can create a different Orange Book expiration pattern than enzalutamide and apalutamide. The generic-entry barrier often remains strong if last-to-expire patents are formulation- or method-of-use-driven.

Competitive framing that affects patent economics

• Treating physicians choose regimens based on efficacy versus tolerability and monitoring.
• Even if active ingredient patents expire, follow-on IP can keep “AB-rated” equivalence from being operationally relevant.
• Payer policy can lock in brand usage through access rules until interchangeability is practically available.

Generic substitution mechanics

• For tablets, bioequivalence studies still must clear FDA standards. Even if ANDA is approved, enforcement of still-active patents can delay commercial marketing.

---

What formulations are protected by androgen receptor antagonist patents?

Featured snippet answer: AR antagonist patent estates commonly protect specific tablet formulations and solid-state forms, including crystalline form specifications, excipient ratios, and dissolution/disintegration properties that help maintain exposure and stability.

Formulation patent categories that matter in practice

• Crystalline form specifications
  • polymorph characterization, XRPD peaks, melting point ranges
• Particle size and morphology
  • controls dissolution rate and bioavailability
• Solvate and water-content control
  • reduces variability in manufacturing and performance
• Tablet excipient and release profile
  • disintegration and dissolution thresholds
• Coating and stability patents
  • moisture uptake and degradation behavior

Why formulation patents delay ANDA “launch on approval”

• Even when FDA approves an ANDA, patent litigation can enjoin marketing for certain strengths or indications.
• If a generic designs a non-infringing formulation, it may still face method-of-use constraints.

---

What method-of-use patents block generic launches for AR antagonists?

Featured snippet answer: Method-of-use patents for AR antagonists block generic launches by tying treatment to disease state and lines of therapy, creating a second barrier even after chemical and formulation patents expire.

Method-of-use claim patterns

• “Treating” language plus:
  • mCRPC or nmCRPC definitions,
  • post-docetaxel status,
  • prior androgen deprivation therapy baseline,
  • monitoring metrics (PSA response criteria) used as inclusion language.

Litigation focus points

• Whether the generic’s proposed label or instruction induces infringement.
• Whether generic labeling triggers induced infringement theories based on the method-of-use claims.

---

What biosimilar risk exists for androgen receptor antagonists?

Featured snippet answer: Biosimilar risk is limited because AR antagonists are small molecules, not biologics. The primary generic threat is ANDA-based small-molecule entry, not biosimilar competition.

Practical competitor categories

• ANDA generic entry (when patent barriers are cleared)
• Authorized generics (contracted distribution when litigation settles)
• Me-too AR inhibitors with different dosing and safety profiles that take share even before generics launch

---

What patent litigation affects the competitive landscape for androgen receptor antagonists?

Featured snippet answer: Competitive dynamics are most affected when litigation reaches the “last-to-expire” patents, typically method-of-use and formulation. Court outcomes and settlements determine whether generics launch at the earliest legally permitted date.

Litigation outcomes that shift market share quickly

• Early summary judgment on claim construction for crystalline and formulation terms
• Settlement that accelerates or delays generic marketing by months to years
• Injunction or covenant terms that constrain distribution channels

Where to expect recurring disputes

• Solid-state form claims
• Tablet dissolution/disintegration and stability claims
• Method-of-use for specific labeled settings

---

What generic entry risks exist for androgen receptor antagonist therapies by the time key patents expire?

Featured snippet answer: The main generic entry risk is that “easy” patent expirations do not translate into immediate market entry because last-to-expire formulation and method-of-use patents can still block commercialization.

Launch scenarios (business-relevant)

1. Full clearance by last-to-expire patent
   • Generic launches broadly for all labeled indications and strengths.
2. Partial clearance
   • Generic can market only after agreeing to carve-outs, limited strengths, or non-covered indications.
3. Delayed market entry despite FDA approval
   • Patent enforcement prevents commercial marketing until resolution.

---

How do AR antagonists compare with each other on patent cliffs and revenue exposure?

Featured snippet answer: Revenue cliffs are determined by the last unexpired Orange Book patent tied to the generic’s intended strength and label scope. Across enzalutamide, apalutamide, and darolutamide, the largest delays typically come from follow-on formulation and method-of-use patents rather than the primary active ingredient.

Side-by-side comparison framework (what matters for planning)

Metric	What to track	Why it matters
Last unexpired Orange Book patent date	Determines earliest carve-out launch	Litigation and settlements often hinge on this date
Patent count by category	Shows likelihood of design-around	Many formulation/use patents increase delay risk
PIV target selection	Predicts injunction likelihood	If method-of-use is targeted late, case leverage changes
Settlement terms	Defines actual launch timeline	Determines at-risk exposure

---

Key Takeaways

• AR antagonists’ patent estates usually extend beyond primary composition via crystalline/formulation and method-of-use families that can block commercialization even after baseline patents expire.
• Generic launch timing is driven by Orange Book “last-to-expire” patents mapped to the generic’s intended dosage form and label scope, with method-of-use claims frequently proving decisive.
• PIV litigation for AR antagonists is typically about forcing resolution on formulation and use patents, with settlements often fixing launch dates and limiting launch scope through covenants and carve-outs.
• Biosimilar risk is not a factor for these small molecules; competition and generic threats come via ANDAs and line-shift dynamics against other AR pathway inhibitors.

---

FAQs

1) How many patents typically remain on an androgen receptor antagonist Orange Book listing at the time of the first PIV filing?

Count by category (composition, formulation, method-of-use) and identify which are last-to-expire relative to the generic’s planned dosage form. The practical count that matters is the unexpired patents asserted or likely to be asserted in the case.

2) What claim types most often survive in AR antagonist PIV litigation?

Crystalline form and tablet formulation claims with specific solid-state or dissolution parameters, and method-of-use claims that tie treatment to disease state and line of therapy.

3) Can an ANDA filer avoid infringement for an AR antagonist by changing the polymorph?

Sometimes. If the estate includes tightly drafted crystalline specifications with evidence-based equivalence language, design-around can still be contested. Many cases revolve around whether the generic’s form is non-infringing by measurable characterization.

4) Does label scope control whether a generic can launch for an AR antagonist?

Yes. If method-of-use patents cover certain indications or patient populations, a generic may face injunction risk or may need label carve-outs depending on settlement and infringement theories.

5) What is the fastest path to generic entry for AR antagonists after patent expirations?

Resolution of the last-to-expire formulation and method-of-use patents, often through settlement, rather than invalidation of the full estate.

---

References (APA)

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
2. FDA. Drug Approval and Databases: Drugs@FDA. FDA.
3. U.S. Patent and Trademark Office. Patent Public Search. USPTO.